Cogent Biosciences

COGT

Market cap $5.87B

Cogent Biosciences, Inc. maintains a Buy rating as bezuclastinib demonstrates blockbuster potential in GIST and systemic mastocytosis (SM) indications. Bezuclastinib nearly doubled median PFS in 2L GIST (PEAK trial), supporting a high peak market share assumption despite competitive pressures. COGT's sum-of-the-parts valuation yields a fair value of $26.54/share, with current cash reserves likely sufficient to reach commercial launch, though dilution risk remains.

WALTHAM, Mass. and BOULDER, Colo., April 01, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the completion of the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastinib in patients with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with imatinib. Based on the positive results from the PEAK trial, the bezuclastinib NDA was submitted under the FDA's Real-Time Oncology Review (RTOR) program, which is intended to enable a more streamlined review process. Bezuclastinib was also granted Breakthrough Therapy Designation as a treatment for GIST earlier this year.

UBS analysts have outlined a set of high-conviction healthcare ideas where they believed the market was underappreciating earnings durability and the scale of upcoming catalysts, focusing on stocks backed by differentiated views and proprietary insights. In biotechnology, they identified Cogent Biosciences (NASDAQ:COGT) as their top pick, arguing the company offered scarcity value as a SMID-cap advancing two late-stage, potentially blockbuster assets.

RTW Investments added 4,124,755 Cogent Biosciences shares in the fourth quarter; the estimated trade size was $115.95 million. Meanwhile, the quarter-end stake value increased by $219.88 million, reflecting both trading and price appreciation.

Kynam Capital sold 1,720,949 shares of Cogent Biosciences in the fourth quarter; the estimated transaction value was $48.38 million. Meanwhile, the position's quarter-end value changed by $105.74 million, reflecting both trading and share price movements.

Boone Capital Management sold 945,042 shares of Cogent Biosciences in the fourth quarter. As a result, the quarter-end position value decreased by $13.57 million.

Cogent Biosciences jumps after FDA accepts bezuclastinib NDA for treating non-advanced SM, with a decision due by Dec. 30, 2026.

WALTHAM, Mass. and BOULDER, Colo.

Sphera Funds bought 279,974 shares of Cogent Biosciences in the fourth quarter; the estimated transaction value was $7.87 million. The quarter-end position value increased by $12.03 million, reflecting both new shares and stock price appreciation.

Cogent Biosciences, Inc. remains a Buy as bezuclastinib advances toward triple approval in GIST and systemic mastocytosis (advanced, non advanced). Bezuclastinib demonstrated strong efficacy in pivotal trials, with durable clinical benefit and superior symptom improvement versus competitors. COGT's robust cash position ($900.8m) supports its path to commercialization, despite significant R&D-driven losses and competitive risks.